$2bn deal sees uniQure license haemophilia B gene therapy to...

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B. 

CSL, BrightInsight team up on digital health for rare diseas...

CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients with rare diseases manage their conditions.

Plasma firms join forces on “unbranded” coronavirus treatmen...

CSL accuses ex-exec, now at Pharming, of stealing trade secr...

Taking plasma from donor to patient

Lutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how they have shaped the company’s approach to working with and for patients.

CSL Behring lung drug would cost NHS £8m per patient, says N...

NICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it would cost a massive £8 million to give a patient a ye